

CERUS CORP  
Form 8-K  
September 26, 2005

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **September 19, 2005**

## CERUS CORPORATION

(Exact name of registrant as specified in its charter)

**Delaware**  
(State of jurisdiction)

**0-21937**  
(Commission File No.)

**68-0262011**  
(IRS Employer Identification No.)

**2411 Stanwell Drive**  
**Concord, California 94520**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(925) 288-6000**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Edgar Filing: CERUS CORP - Form 8-K

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On September 19, 2005, Cerus Corporation ( Cerus ) received a payment from MedImmune, Inc. ( MedImmune ) in the amount of \$500,000 pursuant to the companies April 2004 Collaboration and License Agreement. The payment represents a development milestone payment earned by Cerus upon the companies joint selection of a lead candidate for a vaccine strain targeting EphA2, an antigen overexpressed in breast, prostate and colon cancers, as well as metastatic melanoma. The vaccine being developed uses Cerus Listeria monocytogenes vaccine platform and MedImmune s EphA2 cancer antigen.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CERUS CORPORATION**

Dated: September 26, 2005

By: /s/ William J. Dawson  
William J. Dawson  
Vice President, Finance and Chief  
Financial Officer